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Background: Polyketides are structurally diverse natural products that have a
range of medically useful activities. Nonaromatic bacterial polyketides are
synthesised on modular polyketide synthase (PKS) multienzymes, in which each
cycle of chain extension requires a different ‘module’ of enzymatic activities.
Attempts to design and construct modular PKSs that synthesise specified novel
polyketides provide a particularly stringent test of our understanding of PKS
structure and function.
Results: We have constructed bimodular and trimodular PKSs based on
DEBS1–TE, a derivative of the erythromycin PKS that contains only modules
1 and 2 and a thioesterase (TE), by substituting multiple domains with
appropriate counterparts derived from the rapamycin PKS. Hybrid PKSs
were obtained that synthesised the predicted target triketide lactones, which
are simple analogues of cholesterol-lowering statins. In constructing
intermodular fusions, whether between modules in the same or in different
proteins, it was found advantageous to preserve intact the acyl carrier
protein–ketosynthase (ACP–KS) didomain that spans the junction between
successive modules. 
Conclusions: Relatively simple considerations govern the construction of
functional hybrid PKSs. Fusion sites should be chosen either in the surface-
accessible linker regions between enzymatic domains, as previously revealed,
or just inside the conserved margins of domains. The interaction of an ACP
domain with the adjacent KS domain, whether on the same polyketide or not, is
of particular importance, both through conservation of appropriate
protein–protein interactions, and through optimising molecular recognition of
the altered polyketide chain in the key transfer of the acyl chain from the ACP of
one module to the KS of the downstream module.
Introduction
Macrocyclic polyketides are a large group of natural prod-
ucts produced principally by actinomycetes using modular
polyketide synthases (PKSs), which are giant multien-
zymes [1–8] housing sets or ‘modules’ of enzymatic activi-
ties, each module being required to catalyse a different
cycle of polyketide chain extension. The erythromycin-
producing PKS (6-deoxyerythronolide B synthase, DEBS),
for example, contains six extension modules distributed
among three dimeric multienzymes DEBS1, DEBS2 and
DEBS3 (Figure 1) [9].
A convenient model system for studying modular PKSs has
been engineered by relocating the DEBS chain-terminating
thioesterase (TE) to the carboxyl terminus of the DEBS1
multienzyme [10,11]. The resulting bimodular PKS
(DEBS1–TE) catalyses the production of triketide lactones
both in vivo and in vitro [10–13]. The DEBS1–TE model
system has been used to demonstrate that interspecies
modular PKSs are functional: transplantating a malonyl-
CoA-specific acyltransferase (AT) domain from extension
module 2 of the rapamycin PKS to replace the methyl-
malonyl-CoA-specific AT domain of extension module 1 of
DEBS gave rise to the expected altered triketide lactones
[14]. Numerous further examples of such AT swaps have
since been reported [15], as well as substitutions of reduc-
tive activities [16]. All these hybrid enzyme constructions
have been guided by the results of extensive mapping,
Addresses: 1Cambridge Centre for Molecular
Recognition and Department of Biochemistry,
University of Cambridge, Tennis Court Road,
Cambridge, CB2 1GA, UK. 2Cambridge Centre for
Molecular Recognition and University Chemical
Laboratory, University of Cambridge, Lensfield
Road, Cambridge, CB2 1EW, UK. 
Present addresses: *Bioprocessing Unit,
GlaxoWellcome Research & Development, Medicines
Research Centre, Gunnels Wood Road, Stevenage,
Herts SG1 2NY, UK. †F. Hoffmann-La Roche AG,
Preclinical Infectious Diseases, Bau 15/223, CH-
4070 Basel, Switzerland. ‡Kluyverlaboratorium voor
Biotechnologie, Technische Universiteit Delft,
Julianalaan 67, 2628 BC Delft, The Netherlands.
§Development Dept, Van den Bergh Foods Ltd,
London Road, Purfleet, Essex RM19 1SD, UK.
Correspondence: Peter F Leadlay
E-mail: pfl10@mole.bio.cam.ac.uk
Key words: hybrid PKS, polyketide synthase,
statins, Streptomyces
Received: 28 May 1999
Revisions requested: 21 June 1999
Revisions received: 6 July 1999
Accepted: 9 July 1999
Published: 14 September 1999
Chemistry & Biology October 1999, 6:731–741
http://biomednet.com/elecref/1074552100600731
1074-5521/99/$ – see front matter 
© 1999 Elsevier Science Ltd. All rights reserved.
Research Paper 731
using limited proteolysis, of domain and linker boundaries
of the DEBS multienzymes [17,18]. The results have
tended to confirm the importance of making fusions at or
near such domain boundaries or in the linker regions.
These partial successes already raise the hope that libraries
of bioactive products might be produced by such methods
[19–22]. In this paper, we examine how our current knowl-
edge of the structure and function of type I PKSs may be
used to design and construct a modular polyketide synthase
to catalyse the synthesis of specified novel products. This is
a stringent test of our understanding, and success would
herald a potentially important role for these enzymes in
chiral synthesis.
Our biosynthetic target is a group of synthetic inhibitors of
hydroxymethylglutaryl-CoA reductase, an enzyme
involved in cholesterol biosynthesis, and the target of
important cholesterol-lowering drugs such as lovastatin,
simvastatin and fluvastatin (Figure 2) [23,24]. The syn-
thetic inhibitors [25] are structurally very much simpler
than these drugs but retain the (4R, 6R)-β-hydroxy-δ-
lactone moiety, which is crucial for bioactivity. For
example, compound 4 (Figure 2) has approximately three
times the activity of natural compactin [26] and simple ana-
logue 5, which also shows a small activity, can be envisaged
as the tetraketide product of a hypothetical trimodular
PKS. This paper demonstrates the feasibility of the stere-
ospecific biosynthesis of compounds 10–13, containing the
target (4R, 6R)-β-hydroxy-δ-lactone moiety (Figure 1),
using designer bimodular PKSs. We also show how this
approach can be extended to a trimodular system, generat-
ing tetraketides 6 and 7, which are even closer structural
analogues of 5.
Results and discussion
Assembly of bimodular PKS multienzymes for production
of lactones 10 and 11 by recombinant Saccharopolyspora
erythraea
The target compounds 12 and 13 differ from the lactones 8
and 9 normally produced by DEBS1–TE in having no
methyl substituent at either C-2 or C-4, and having an
opposite configuration of the hydroxyl group at C-3.
Several routes were considered for the construction of a
suitable hybrid PKS gene starting from DEBS1–TE, all of
which exploited the availability of the cloned and
sequenced DNA for the entire rapamycin PKS from Strep-
tomyces hygroscopicus [5,6]. A number of genetic modifica-
tions to module 2 were examined. Substitution of the
entire module 2 of DEBS1–TE, from a position in the
middle of the ACP1 domain to an equivalent position in
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The erythromycin-producing polyketide synthase (PKS); primary
organisation of the genes and their corresponding protein domains.
There are six chain extension modules, each beginning with a KS
domain, that are responsible for adding the six successive C3 units. The
loading module (LM) specifies propionate as the starter unit. The
completed chain is released as a macrolactone by the thioesterase (TE)
domain. AT, acyltransferase; ACP, acyl carrier protein; KS, ketosynthase;
KR, β-ketoacyl reductase; DH, dehydratase; ER, enoylreductase. 
ACP2, with an equivalent region from rap module 12, pro-
duced the triketide lactone synthase TKS–AR2, which
was predicted to give rise to compounds 10 and 11
(Figure 3). To test the possibility that efficient transfer of
the growing polyketide chain between modules might be
promoted by preserving adjacent ACP and KS domains
intact [27], a second hybrid PKS (TKS–AR3) was made,
similar to TKS–AR2 except that the acyltransferase (AT),
ketoreductase (KR) and ACP domains of rap module 12
were fused to the carboxyl terminus of the DEBS KS2
domain, so that the ACP1–KS2 didomain was undisturbed.
To construct TKS–AR2, module 2 was excised from
DEBS1–TE to create a diketide synthase in which the
DNA for module 1 ACP is fused to that for module 2
ACP at an engineered unique BglII site, at a position 4–5
amino acids amino-terminal of the 4′-phosphopanteth-
eine attachment site. The entire rap module 12 DNA
was amplified by the polymerase chain reaction (PCR)
and cloned into this BglII site to create the chimaeric
TKS. However, when this gene was expressed in a
plasmid expression system in Streptomyces coelicolor
[14,28] and the broth analysed for the production of trike-
tide lactones using gas chromatography–mass spectrome-
try (GC–MS), none was found. The reasons for the
inactivity of this hybrid synthase could include
unfavourable protein–protein interactions between the
two halves of the chimaeric ACP1/11. A DEBS1–TE
mutant gene was therefore constructed in which the
same BglII site was introduced into the DNA for both
ACP1 and ACP2, leading to point mutations
Glu1969→Asp and Glu3415→Asp respectively. The
gene was expressed in S. coelicolor CH999, and it was
shown that these two mutations were sufficient to render
the synthase inactive. 
To construct TKS–AR4, the starting point was a plasmid
(pARE62) whose insert comprises the DEBS loading
module (AT0-ACP0), linked via an engineered NheI site
in the linker region between the ACP0 and KS1 domains
(Figure 4) to the rap modules 11 and 12, in turn fused at
the carboxyl terminus to the DEBS chain-releasing
thioesterase (TE), via a unique NotI site in the linker
region between rap module 12 ACP domain and the TE
(Figure 4). The construction of pARE62 is given in the
Supplementary material. For TKS–AR3, a unique HindIII
site was engineered in the linker region between DEBS
KS2 and rap module 12 AT (Figure 4). The DNA for rap
module 12 (AT–KR–ACP) and TE was fused to the 3′ end
of the DNA for the loading module and module 1 KS2 of
DEBS1–TE, in place of the loading module and rap
module 11–module 12 KS (Figure 3). This hybrid PKS
gene, and all the others discussed below, were housed in
an SCP2*-based expression plasmid [29] in S. erythraea
JC2, a strain from which the erythromycin PKS genes
have been deleted. This system gives consistently higher
yields of polyketide than are obtained in a comparable
expression system [28] in S. coelicolor. 
The broth from recombinant S. erythraea containing this
hybrid gene (TKS–AR3) was shown, using GC–MS, to
contain two triketide lactones with exactly the masses
expected for compounds 10 and 11 (Figure 3). These lac-
tones were purified and their structures were confirmed as
10 and 11, using nuclear magnetic resonance (NMR), MS
and MS–MS analysis. The isolated yields (1.0 mg l–1 of 10
and 2.4 mg l–1 of 11) were only about 10% of those
expected for the products of DEBS1–TE, but these
results clearly established the feasibility of manipulating
whole modules to create chimaeric PKS multienzymes.
The reasons for the low yields have not yet been investi-
gated in detail, but could include: decreased transcription
levels or lower mRNA stability; poor folding or stability of
the hybrid multienzyme; or imperfect protein–protein
contacts particularly across fusion boundaries. 
Assembly of bimodular PKS multienzymes for production
of lactones 12 and 13 by recombinant S. erythraea
Having established a route to achieve the desired modi-
fications in module 2, several further hybrid enzymes
were constructed that were expected to direct the pro-
duction of the target lactones 12 and 13 in which both
branching methyl groups are missing (Figure 3). As
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Figure 2
Chemical structures of cholesterol-lowering statins that act as
inhibitors of HMG-CoA reductase. lovastatin (1), compactin (2),
simvastatin (3). Synthetic and biosynthetic analogues which show
statin activity include the aryl analogues 4 and 5. Compounds 6 and 7
are potential biosynthetic structural analogues of the statin family.
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Domain organisation of hybrid bimodular PKS multienzymes made in this study. 
already mentioned, plasmid pARE62 contains the hybrid
TKS–AR4, in which the entire rap modules 11 and 12
are sandwiched between the DEBS loading module and
the DEBS chain-terminating TE. These modules are
predicted to dictate the formation of a triketide contain-
ing acetate extender units with exactly the required
stereochemistry at each hydroxyl group [5,6,30]. To
provide a direct assessment of the value of preserving
adjacent ACP–KS domains intact, a fourth hybrid syn-
thase was constructed (TKS–AR5) in which the rap
module 11 KS domain was replaced by the DEBS KS1,
so that the fusion point in the hybrid lay in the linker
region between KS1 and the rap module 11 AT domain,
at an engineered HindIII site (Figure 4). When the gene
for multienzyme TKS–AR4 was expressed in recombi-
nant S. erythraea JC2, the broths were found, using
GC–MS analysis, to contain no trace of triketide lac-
tones. However, low levels of the target molecules 12
and 13 were detected in the broth from the recombinant
strain of S. erythraea harbouring TKS–AR5. A synthetic
sample of the lactone 12 was synthesised in four steps
(Figure 5) and was shown to have identical retention
time in GC–MS to the material obtained from the broth.
Again, it appears that maintaining the juxtaposition of
the native ACP0 of the loading module with the KS1
domain was beneficial, although the effect has not yet
been precisely quantified. The fusion point in the inter-
modular loading module-KS1 linker region of AR4 is
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Figure 4
Amino acid sequence around fusion sites in
hybrid PKSs based on ery and rap PKS
modules. Restriction enzyme sites were
introduced into the encoding DNA at the
positions shown. The amino acid sequences
of native interdomain linker regions are given
for comparison.
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very similar to that in a productive fusion of the aver-
mectin PKS loading module and ery module 1 [31] and to
the fusion of the ery module 1 and rifamycin PKS
module 5 described recently [32] and correctly predicted
to be functional. The fact that the AR4 fusion is inactive
may indicate that further work is needed before such
predictions can be generally made.
An alternative approach to the target compounds 12 and 13
was pursued. The TKS–AR3 synthase was further modified
by replacement of the DEBS AT1 domain, (which is spe-
cific for the loading of methylmalonyl-CoA [30]), by the rap
module 2 AT domain, (which is specific for the loading of
malonyl-CoA [14]), to form TKS–AR6 (Figure 3). Oliynyk et
al. [14] showed that this substitution does not lead to a sig-
nificant drop in yield of lactone (less than twofold). Plasmid
pIB103 contains the DEBS1–TE gene in which a unique
HindIII site has been introduced in the linker region
between the DEBS KS2 and AT2 domains. The DEBS
loading module and most of DEBS module 1 were excised
on a specific NdeI–SfuI fragment and this was replaced with
a counterpart fragment from plasmid pMAT2 [14] in which
the AT1 domain is replaced by the AT domain from rap
module 2. Finally, the DEBS module 2 AT, KR and ACP
domains, together with an additional 3′ region, were excised
on a HindIII fragment and replaced by a HindIII fragment
from plasmid pKS12A (see the Materials and methods
section) containing the counterpart domains from rap
module 12 (Figure 3). Recombinant S. erythraea cells con-
taining TKS–AR6 were grown and analysed for the pres-
ence of triketide lactones. GC–MS analysis showed the
presence of both 12 and 13, in an approximate ratio of 1:2.
The compound identified as 12 showed a retention time
and MS fragmentation pattern identical to that of synthetic
12. The recombinant strain was grown on solid medium and
the lactones were extracted from the plates and purified
using silica gel chromatography and preparative high-perfor-
mance liquid chromatography (HPLC). The identity of the
purified lactones (about 1 mg l–1 of each) was confirmed
using MS and NMR spectroscopy as 12 and 13. 
Use of native ACP and KS domains to mediate interprotein
polyketide chain transfer 
In parallel with the above experiments, we tried another
method of preserving a native ACP–KS didomain intact.
As indicated in Figure 3, this recombinant PKS, TKS–JC1
contained two proteins derived from DEBS1 and DEBS2.
The first consisted of the loading module of DEBS and
DEBS module 1 KS, AT, and KR domains, fused to the
ACP domain of module 2. The second protein contained
DEBS module 3, fused to the chain-terminating TE (see
the Materials and methods section for the construction of
recombinant plasmids). The recombinant strain was
grown on solid medium and the lactones were extracted
from the plates and purified using silica gel chromatogra-
phy and preparative HPLC. The purified lactones were
confirmed, by MS and NMR spectroscopy, to be 14 and
15, both obtained in excellent yields (35 mg l–1 of each).
This result, in which the productive transfer of a polyke-
tide chain from module 1 to module 3 of DEBS is medi-
ated by the ACP domain of module 2, clearly shows the
advantage of keeping the contacts between an ACP and
the following KS domain as near native as possible. In a
recent paper [32], it has been elegantly shown that, in
several cases, the transfer can be effective even if only the
region carboxy-terminal of the ACP domain and amino-
terminal of the KS domain (the ‘linker’ regions) are main-
tained. These results provide interesting confirmation of
the predictions embodied in a general model previously
proposed [18] for the assembly of modular polyketide syn-
thases, in which the strongest contacts are between two
copies of each module, interacting across the subunit
interface in a dimer, and the contacts between successive
modules are limited to adjacent ACP and KS domains. 
Assembly of a trimodular PKS multienzyme for production
of lactones 6 and 7 by recombinant S. erythraea
A trimodular PKS capable of the synthesis of tetraketides
6 and 7 was then designed (Figure 6) and consisted of ery
module 1 and rap modules 11 and 12, with the rap
module 11 KS domain replaced by the ery KS2 domain. To
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Figure 5
Synthesis of (4R,6R)-4-hydroxy-
methyltetrahydropyran-2-one [12]. (i) TBS-
OTf, Et3N, DCM, 0°C→rt. (ii) DIBAL-H, DCM,
–78°C→rt. (iii) CrCl2, LiI, THF, 0°C→rt.
(iv) LiOH, H2O2, THF/H2O, 0°C→rt. (v) 1 M,
HCl, THF, 40°C.
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construct this PKS (TKS–AR7), the amino-terminal region
upstream of the AT domain of rap module 11 in TKS AR5
(Figure 3) was replaced with the ery loading module, ery
module 1 and domain KS2. The junction covalently
linking the modules was constructed in the linker region
joining the KS2 to the rap module 11 AT at a unique
HindIII restriction enzyme site as in TKS–AR5 (Figure 4).
The final expression plasmid containing the gene for the
hybrid trimodular synthase was then integrated into S. ery-
thraea JC2. Randomly selected colonies were grown in
liquid medium, and the fermentation broth was extracted
and analysed for polyketide products. GC–MS analysis
showed the presence of only two identifiable polyketides,
the target tetraketide lactones 6 and 7. The recombinant
strain of S. erythraea/JC2(pMT1) was grown on solid
medium and the lactones were extracted from the plates,
and purified using silica gel chromatography and prepara-
tive HPLC. The identity of the purified lactones was con-
firmed by MS and NMR spectroscopy as 6 and 7. 
The yields of the products obtained in the above experi-
ments were not optimised, and varied from excellent
(35 mg l–1 of purified triketide for each of 14 and 15) to
modest (about 1 mg l–1 of each tetraketide 6 and 7 to
barely detectable (in the case of triketides 10 and 11 pro-
duced by TKS–AR4). Although the emerging rules for
constructing hybrid type I modular PKS multienzymes
are engagingly simple, some further work is needed to
define the optimum fusion sites to choose within the
linker regions between domains (see also the recent
elegant work of Gokhale et al. [32]); to identify the most
versatile natural modules and domains to deploy; and to
enhance the production and stability of recombinant
PKS proteins. Thus, the relatively high yield we have
found for the production of 14 and 15 by TKS–JC1
focuses attention on the linker region between the
reductive domains (dehydratase–enoylreductase–ketore-
ductase) and the ACP domain, in future efforts to assem-
ble modules systematically. Part of the superior
efficiency of TKS–JC1 may arise from the fact that trans-
fer occurs between modules housed in different multien-
zymes, but further work is needed to clarify this issue.
DNA shuffling methodologies can also be employed if a
suitable assay is available [33,34]. 
The successful specific production of triketides and
tetraketides using rationally designed modular PKSs is
obviously encouraging for further work aimed at produc-
ing 5 in a single-step fermentation. This future work
needs to address two specific problems: a synthase is
required in which the first module employs an acetate
chain extender and processes this as far as a double bond
rather than a hydroxyl function. These changes could be
achieved by rational engineering of ery module 1 or by
using another appropriate module. Futhermore, a loading
module is required that accepts CoA esters of benzoic and
other aryl acids; and finally, a suitable source of aryl acid
units must be present, either by biosynthesis or by addi-
tion to the fermentation, together with a mechanism for
their activation.
Significance
Modular polyketide synthases (PKSs) are potentially
valuable for the biosynthesis of novel complex polyke-
tides. The demonstration that a designed hybrid trimodu-
lar polyketide synthase catalyses the predicted formation
of a simple analogue of the cholesterol-lowering statins
illustrates the principle of designing a PKS to conduct
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Figure 6
Domain organisation of the hybrid trimodular
polyketide synthase TKS–AR7. 
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chiral synthesis. This artificial synthase is multimodular
and is therefore more suitable for designed alterations of
structure than the single modular PKS implicated in the
natural biosynthesis of lovastatin [35]. The ability to
manipulate whole modules is of particular importance
for the de novo assembly of complex molecules. The
results show that the interaction between an acyl carrier
protein (ACP) domain and the adjacent ketosynthase
(KS) domain is crucial for efficient intermodule chain
transfer, both between modules housed in the same
multienzyme and between modules in successive multi-
enzymes of the PKS. It is not yet apparent, however,
whether the entire ACP–KS didomain region has to be
preserved. The hybrid PKSs are significantly less effi-
cient than the natural PKS multienzymes from which
they have been derived, but there are obvious opportuni-
ties for further optimisation, especially through the use of
alternative domains and modules from natural sources
and the given choice of alternative fusion sites in the
inter-domain linker regions.
Materials and methods
Strains and plasmids
S. erythraea/JC2 was maintained as described previously [29].
Routine cloning and transformation procedures were as previously
described for Escherichia coli [36] and for Streptomyces [37,38].
Electrocompetent cells of E. coli DH10B strain were made as
described previously [39]. X-gal was obtained from Novabiochem.
Agarose (electrophoresis grade) was obtained from Life Technologies
Inc., casamino acids and tryptone were from Difco laboratories. Glu-
cidex (MD30E), soya flour and beet molasses for SM3 culture media
were the kind gifts of Glaxo Wellcome, UK. All antibiotics were bought
from Sigma Chemical Company, MO, USA. 
DNA manipulations
PCR reactions were performed on a programmable Robo Cycler Gradient
40 (Stratagene, USA) according to a modification of a protocol described
earlier [40]. Automated DNA sequencing was carried out on double-
stranded DNA templates using an automated ABI 373A sequencer
(Applied Biosystems). RecA protein was purchased from Promega.
Chemical analysis
1H NMR spectra were recorded at 600 MHz on a Bruker DRX-600, at
500 MHz on a Bruker DRX-500, at 400 MHz on a Bruker AM-400 or
Bruker DRX-400, and at 250 MHz on a Bruker AC-250. 13C NMR
spectra were recorded at 100 MHz on a Bruker AM-400 or at
100 MHz on a Bruker DRX-400. 1H NMR and 13C NMR spectra were
referenced internally to CHCl3 (7.27 and 77.5 ppm respectively).
J Values are given in Hz. Chromatography was carried out using Merck
Kieselgel 60 (40–63 µm). GC–MS was performed on a Finnigan MAT
GCQ instrument. Analytical and preparative reverse-phase HPLC–MS
analysis was carried out using Phenomenex Prodigy 5 µ ODS3 100 Å
columns with the following dimentions: 250 × 4.6 mm (analytical),
250 × 10.0 mm (semi-preparative) and 250 × 21.2 mm (preparative) on
a Finnigan MAT LCQ instrument. Mass spectra were recorded on a
Kratos MS 890 double focussing magnetic sector MS (EI) and a
Bruker Bio Apex II Fourier Transform Ion Cyclotron Resonance (FT-
ICR, 4.7 Tesla), (ESI). Optical rotations were recorded on a Perkin
Elmer 241 polarimeter. Solvents were dried under standard conditions. 
Growth medium
Special Medium 3 (SM3) (for 1 l); Glucose 5 g, MD30E-glucidex 50 g,
soya bean flour 25 g, beet molasses 3 g, K2HPO4 0.25 g, CaCO3
2.5 g, Milli-Q water to 1 l and pH adjusted to 7.0 with KOH.
Construction of expression plasmids pBgAR4 and pARE62 for
the hybrid synthases TKS–AR2 and TKS–AR4 respectively
The construction of these expression plasmids is described in detail in
the Supplementary material.
Construction of plasmid pO15-111224 for the hybrid
synthase TKS-AR5
Plasmid pKS11A (the construction of which is described in the supple-
mentary material) was cut with Hind III and the 10 kbp fragment con-
taining the gene encoding for rap module 11, rap module 12 and ery
TE was ligated to the vector pIBO15 [27] previously cut with Hind III.
E. coli DH10B cells were transformed with the ligation mixture and
selected colonies were screened for their plasmid content. The desired
plasmid pO15-111224 was identified by restriction mapping.
Construction of plasmid pIBM1
Plasmid pMAT2 [14] was cut with NdeI and Sfu I and the 4.6 kbp frag-
ment containing the gene encoding the ery loading module, and ery
module 1 with the rap AT2 domain, was ligated to plasmid pIB103 previ-
ously cut with NdeI and Sfu I. Plasmid pIB103 contains the gene for the
DEBS1-TE synthase. The ligation mixture was used to transform E. coli
DH10B cells and selected colonies were screened for their plasmid
content. The desired plasmid pIBM1 was identified by restriction mapping.
Construction of plasmid pAT-1224 for the hybrid synthase
TKS–AR6
Plasmid pKS12A (the construction of which is described in the Sup-
plementary material) was cut with Hind III and the 5.4 kbp fragment
containing the gene encoding rap module 12 and ery TE was ligated to
plasmid pIBM1 previously cut with Hind III. E. coli DH10B cells were
transformed with the ligation mixture and selected colonies were
screened for their plasmid content. The desired plasmid pAT-1224 was
identified by restriction mapping.
Construction of plasmid p103-1224 for the hybrid synthase
TKS–AR3
Plasmid pKS12A was digested with Hind III and the 5.4 kbp fragment
containing the gene encoding rap module 12 and ery TE was ligated to
plasmid pIB103 previously cut with Hind III. E. coli DH10B cells were
transformed with the ligation mixture and selected colonies were
screened for their plasmid content. The desired plasmid p103-1224
was identified by restriction mapping.
Construction of plasmid p103-111224 for the hybrid synthase
TKS-AR7
Plasmid pKS11A was cut with Hind III and the 10.0 kbp fragment contain-
ing the fragment encoding rap module 11 (minus the KS11 domain), rap
module 12 and ery TE was ligated to plasmid pIB103 previously cut with
Hind III. E. coli DH10B cells were transformed with the ligation mixture
and colonies were selected for resistance to ampicillin. Plasmid DNA iso-
lated from ampicillin-resistant clones was mapped by restriction enzyme
digestion and the desired plasmid was designated p103-111224.
Construction of pE1
A PCR product containing DNA encoding for the erythromycin KR1
domain was obtained using oligonucleotides 5′−GCCTAGGCACCG-
GAGCACGCCGGGTGCCCTT-3′ and 5′−CGTTAACGCGCCCAC-
CCGCGGTTCGGCCGGCGCCT-3′ using pNTEP2 [14] as template.
This product was cloned into pUC18 previously digested with SmaI to
produce plasmid pCRE1. This plasmid was digested with Avr II and
HpaI and the 1.8 kbp insert was cloned into pJLK14 (construction of
this plasmid will be described elsewhere) previously digested with
Avr II and HpaI to obtain plasmid pE1. Plasmid pE1 encodes a triketide
synthase D1TE where KR2 has been replaced by KR1. 
Construction of pDKS
Plasmid pEI was digested with NspV and religated, the resulting
plasmid encodes a diketide synthase containing ery LM, KS1, AT1,
KR1 and ACP-TE from D1TE. 
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Construction of pDKSH for the hybrid synthase TKS-JC1
A PCR product containing DNA encoding from the start of the ery-
thromycin ACP domain of module 2 to the end of the inactive KR
domain of module 3 was obtained using oligonucleotides 5′-ATGT-
TAACGGGTCTGCCGCGTGCCGAGCGGAC-3′ and 5′-ATGTTAAC-
CGTTGTGCCGGCTCGCCGGTCGGTCC-3′ using plasmid pBK25
[3] as template. This product was cloned into pUC18 previously
digested with SmaI to produce plasmid pMOD3. This plasmid was
digested with HpaI and the 6.1 kbp insert was cloned into pDKS previ-
ously digested with HpaI to obtain plasmid pDKSH. This plasmid
encodes a two protein triketide synthase containing, in one polypeptide
ery LM, KS1, AT1, KR1 and ACP2 and in the second polypeptide, KS3,
AT3, the inactive KR3 domain and ACP-TE from D1TE. 
Construction of S. erythraea/JC2(pO15-111224),
S. erythraea/JC2(pAT-1224), S. erythraea/JC2(p103-1224),
S. erythraea/JC2 (pMT1) and S. erythraea/JC2(pDKSH)
S. erythraea/JC2 protoplasts were transformed with the expression
plasmids and colonies were selected through resistance to thiostrep-
ton upon integration of the plasmid into the S. erythraea chromosome.
Single transformants were picked and grown on ‘tap-water medium’
plates supplemented with thiostrepton following which single transfor-
mants were grown in SM3 liquid/solid medium supplemented with
5 µg ml–1 of thiostrepton as described in the analysis. 
Analysis
Isolation of (4R,5R,6R) 5,6-dimethyl-4-hydroxy-tetrahydropy-
ran-2-one (10) and (4R,5R,6R) 6-ethyl-4-hydroxy-5-methyl-
tetrahydropyran-2-one (11). S. erythraea/JC2 (p103-1224) was
grown on five special medium (SM3) agar plates, from an initial inocu-
lum in tryptic soy broth (TSB) liquid medium (30°C, 300 rpm, 3 days).
After 24 days the agar was extracted with ethyl acetate/2% formic acid
(5 × 250 ml). The combined organic extracts were neutralised with
NaHCO3, dried over Na2SO4 and concentrated in vacuo. The concen-
trated extract was passed through silica gel eluting with diethyl ether
(300 ml) followed by ethyl acetate (300 ml). The eluent was concen-
trated and purified by silica column chromatography (EtOAc/Petroleum
ether, 2:1) Appropriate fractions were combined and further purified by
preparative reverse phase HPLC–MS (H2O, MeOH) to yield lactones
10 and 11 (1.0 mg l–1 and 2.4 mg l–1 respectively).
(4R,5R,6R) 5,6-Dimethyl-4-hydroxy-tetrahydropyran-2-one (10).
1H NMR (500 MHz, CDCl3) δ = 4.90 (dq, 1 H, J = 3.0 and 6.8, 6–H),
4.06 (m, 1 H, 4–H), 2.82 (dd, 1 H, J = 5.5 and 18.3, 3–Hax), 2.53 (ddd,
1 H, J = 0.9, 3.4 and 18.3, 3–Heq), 1.91 (ddq, 1 H, J = 3.0 and 7.3,
5–Heq), 1.33 (d, 3 H, J = 6.8, C6-Me), 0.97 (d, 3 H, J = 7.3, C5-Me); MS
(ESI) m/z C7H12O3Na calc’d 167.0675080, found 167.0678634
[M + Na]+.
(4R,5R,6R) 6-Ethyl-4-hydroxy-5-methyl-tetrahydropyran-2-one
(11). 1H NMR (500 MHz, CDCl3) δ = 4.61 (ddd, 1 H, J = 3.0, 5.5 and
8.3, 6–H), 4.06 (m, 1 H, 4–H ), 2.82 (dd, 1 H, J = 5.5 and 18.3, 3–H),
2.54 (dd, 1 H, J = 3.4 and 18.3, 3–H), 1.96 (m, 1 H, 5–Heq), 1.78 (ddq,
1 H, J = 7.3, 8.3 and 13.6, CHHCH3), 1.55 (ddq, 1 H, J = 5.5, 7.3 and
13.6, CHH CH3), 1.03 (t, 3 H, J = 7.3, CH2CH3), 0.94 (d, 3 H, J = 7.3,
C5–Me). 13C NMR (100 MHz, CDCl3) δ = 170.3 (2–C), 79.5 (6–C),
68.8 (4–C), 37.1, 35.6, 24.9 (CH2CH3), 10.2 (CH3), 10.0 (CH3). (ESI)
m/z C8H14O3Na calc’d 181.0831880, found 181.0835134 [M + Na]+.
Isolation of (4R,6R) 4-hydroxy-6-methyl-tetrahydropyran-2-one
(12) and (4R,6R) 6-ethyl-4-hydroxy-tetrahydropyran-2-one
(13). S. erythraea/JC2(pAT-1224) was grown on six SM3 agar plates,
from an initial inoculum in TSB liquid medium (30°C, 300 rpm, 3 days).
After 29 days the agar was extracted with ethyl acetate/2% formic acid
(6 × 250 ml). The combined organic extracts were neutralised with
NaHCO3, dried over Na2SO4 and concentrated in vacuo. The concen-
trated extract was passed through silica gel eluting with diethyl ether
(1.5 l), ethyl acetate (2 l) and the eluent was concentrated. Reverse-
phase HPLC–MS (H2O, MeOH) afforded lactones 12 and 13. Fractions
containing required products were extracted into DCM. The combined
organic extracts were dried over Na2SO4 and concentrated in vacuo to
yield lactones 12 and 13 (about 1 mg l–1 of each). The GC–MS trace of
a crude broth extract containing lactone 12 was recorded. The peak
corresponding to 12 had a retention time identical to that of the syn-
thetic standard triketide 12. A sample of the crude extract was ‘spiked’
(3:1 v/v) with a sample of its synthetic standard. The peak correspond-
ing to 12 increased in intensity with respect to all other peaks in the
extract (as confirmed by peak integration). This allowed for verification of
the identity of the acetate-starter lactone (12).
(4R,6R) 4-Hydroxy-6-methyl-tetrahydropyran-2-one (12). 1H
NMR (500 MHz, CDCl3) δ = 4.84 (ddq, 1 H, J = 3.0, 6.4 and 11.1,
6–H), 4.39 (m, 1 H, 4–H), 2.74 (dd, 1 H, J = 5.1 and 17.5, 3–Hax), 2.61
(ddd, 1 H, J = 1.7, 3.8 and 17.5, 3–Heq), 1.97 (dddd, 1 H, J = 1.7, 3.0,
3.8 and 14.5, 5–Heq), 1.75 (ddd, 1 H, J = 3.4, 11.1 and 14.5, 5–Hax),
1.41 (d, 3 H, J = 6.4, C6–Me); MS (ESI) m/z C6H10O3Na calc’d
153.0522134, found 153.0520930 [M + Na]+.
(4R,6R) 6-Ethyl-4-hydroxy-tetrahydropyran-2-one (13). 1H NMR
(500 MHz, CDCl3) δ = 4.67 (dddd, 1 H, J = 3.0, 5.3, 7.1, and 11.3,
6–H), 4.40 (m, 1 H, 4–H), 2.75 (dd, 1 H, J = 5.1 and 17.5, 3–Hax), 2.62
(ddd, 1 H, J = 1.7, 3.8 and 17.5, 3–Heq), 1.96 (dddd, 1 H, J = 1.7, 3.0,
3.4 and 14.5, 5–Heq), 1.75 (m, 2 H, 6–CHH, 5–Hax), 1.67 (m, 1 H,
C6–CHH), 1.03 (t, 3 H, J = 7.3, CH2CH3); (ESI) m/z C7H12O3Na
calc’d 167.0678634, found 167.0681550 [M + Na]+.
Isolation of (4R,6R) 4-hydroxy-6-(1′S-methyl-2′R-hydroxy)pro-
pyl-tetrahydro-pyran-2-one (6) and (4R,6R) 6-(1′S-methyl-2′R-
hydroxy)butyl-4-hydroxy-tetrahydro-pyran-2-one (7). S. erythraea/
JC2 (pMT1) was grown on five SM3 agar plates, from an initial inocu-
lum in TSB liquid medium (30°C, 300 rpm, 3 days). After 25 days the
agar was extracted with ethyl acetate/2% formic acid (5 × 250 ml). The
combined organic extracts were neutralised with NaHCO3, dried over
Na2SO4 and concentrated in vacuo. The residue was purified by flash
column chromatography eluting with diethyl ether (300 ml), DCM
(300 ml) and DCM/methanol (8:2 × 1 l, 7:3 × 1 l and 6:4 × 1 l). The
concentrated eluent was further purified by reverse-phase HPLC–MS
(H2O, MeOH), and concentration of appropriate fractions in vacuo
yielded lactones 6 and 7 (about 1 mg l–1 of each).
(4R,6R) 4-Hydroxy-6-(1′S-methyl-2′R-hydroxy)propyl-tetrahy-
dro-pyran-2-one (6). 1H NMR (600 MHz, CDCl3) δ = 4.89 (dt, 1 H,
J = 3.8 and 10.9, 6–H), 4.44 (m, 1 H, 4–H), 4.08 (dq, J = 3.3 and 6.2,
2′–H), 2.74 (dd, 1 H, J = 4.8 and 17.6, 3–Hax), 2.63 (ddd, 1 H, J = 1.9,
3.3 and 17.6, 3–Heq), 1.96 (m, 2 H, 2 × 5–H), 1.65 (m, 1 H, 1′–H) 1.25
(d, 3 H, J = 6.2, 3′–Me), 1.04 (t, 3 H, J = 7.3, C1′–Me); MS (ESI) m/z
C9H16O4Na calc’d 211.0933010, found 211.0940774 [M + Na]+.
(4R,6R) 6-(1′S-Methyl-2′R-hydroxy)butyl-4-hydroxy-tetrahydro-
pyran-2-one (7). 1H NMR (500 MHz, CDCl3) δ = 4.85 (ddd, 1 H,
J = 4.7, 6.8 and 8.1, 6–H), 4.43 (m, 1 H, 4–H), 3.75 (ddd, 1 H, J = 3.0,
5.1 and 7.7, 2′–H) 2.74 (dd, 1 H, J = 5.1 and 17.5, 3–H), 2.65 (m, 1 H,
3–H), 1.95 (m, 2 H, 2 × 5–H), 1.75 (ddq, 1 H, J = 3.0, 4.7 and 7.3,
1′–H), 1.55 (m, 2 H, 2 × 3′–H), 1.02 (d, 3 H, J = 7.3, C1′–Me), 0.96 (t,
3 H, J = 7.3, 4′–Me); MS (ESI) m/z C10H18O4Na calc’d 225.1095180,
found 225.1097274 [M + Na]+.
Synthesis of (3R)-3-(t-Butyldimethylsiloxy)-butyrate (16) [41].
Methyl (3R)-3-hydroxybutyrate (3.8 ml, 34 mmol, 1.0 eq.) was dissolved
in DCM (50 ml), cooled to 0°C and stirred under argon. Following the
addition of t-butyldimethylsilyltrifluoromethylsulfonate (TBS-triflate,
12 ml, 51 mmol, 1.5 eq.), the mixture was stirred for 10 min and triethy-
lamine (12 ml, 85 mmol, 2.5 eq.) was added. The solution was allowed
to warm to room temperature, stirred for 2.5 h and quenched with brine
(50 ml). The aqueous layer was extracted with DCM (3 × 50 ml). Com-
bined organic extracts were washed with NaOH (pH 11) and dried
over Na2SO4. Flash column chromatography (Rf 0.53, 5% ethyl acetate
in light petroleum) afforded the pure product 16 as a colourless oil
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(5.0 g, 64%); 1H NMR (400 MHz, CDCl3) δ = 4.27 (m, 1 H, 3–H),
3.66 (s, 3 H, OMe), 2.48 (dd, 1 H, J = 7.7 and 14.5, 2-CHH), 2.37 (dd,
1 H, J = 5.3 and 14.5, 2–CHH), 1.19 (d, 3 H, J = 6.1, 4–Me), 0.86 (m,
9 H, t-Bu), 0.06 (s, 3 H, Si–CH3), 0.04 (s, 3 H, Si–CH3); 13C NMR
(100 MHz, CDCl3) δ = 172.1, 65.8, 51.4, 44.7, 25.7, 23.9, 17.9, –4.5,
–5.1; υmax (thin film)/cm–1 1742.6 (C = O); [α]D –28.2 (c 0.44 CHCl3);
MS (ESI) m/z calc’d 233.15772, found 233.15772 [M]+.
Synthesis of (3R)-3(-t-Butyldimethylsiloxy)-butanal (17) [41].
(3R)-3-(t-Butyldimethylsiloxy)-butyrate (16) (5.0 g, 22 mmol, 1.0 eq) was
dissolved in DCM (100 ml) and cooled to (78°C under argon. DIBAL-H
(22 ml, 22 mmol, 1.0 eq of a 1 M solution in DCM) was added and the
solution was stirred at –78°C for a further 1 h. The reaction was
quenched by the addition of a saturated solution of Rochelle’s salt
(potassium sodium tartrate tetrahydrate, 50 ml), allowed to warm to
room temperature, and stirred for 1 h. The aqueous layer was extracted
with DCM (3 × 100 ml). The combined organic extracts were dried over
Na2SO4 and reduced in vacuo. Flash column chromatography (2% ethyl
acetate in light petroleum) afforded the pure product 17 as a colourless
oil (3.6 g, 82%); Rf 0.47, 5 % ethyl acetate in light petroleum; 1H NMR
(400 MHz, CDCl3) δ = 9.80 (t, 1 H, J = 2.4, 1–H), 4.35 (m, 1 H, 3–H),
2.55 (ddd, 1 H, J = 2.8, 6.8, and 15.7, 2–CHH), 2.46 (ddd, 1 H, J = 2.0,
5.0, and 15.7, 2–CHH), 1.24 (d, 3 H, J = 6.2, 4–Me), 0.87 (s, 9 H, t-
Bu), 0.07 (s, 3 H, Si–CH3), 0.06 (s, 3 H, Si–CH3); 13C (100 MHz,
CDCl3) δ = 202.2, 64.5, 53.0, 25.7, 24.2, 17.9, –4.4, –5.0; υmax (thin
film)/cm–1 1729.2 (C = O) [α]D –10.8 (c 5.15 CHCl3); MS (ESI) m/z
calc’d 225.1281274, found 225.1286420 [M + Na]+.
Synthesis of (4S)-3-[(3′R,5′R)-5′-[(t-Butyldimethylsilyl)oxy]-3′-
hydroxyhexanoyl]-4-phenylmethyl-2-oxazolidinone (18) [42].
(4S)-3-Bromoacetyl-4-phenylmethyl-2-oxazolidinone [41] (1.2 g,
4.0 mmol, 1.0 eq.) was dissolved in THF (15 ml) and stirred at 0°C.
(3R)-3(-t-Butyldimethylsiloxy)-butanal (17) (0.90 g, 4.4 mmol, 1.1 eq.)
was dried azeotropically over benzene, dissolved in THF (5 ml) and
added to the mixture. Anhydrous chromium(II) chloride (1.24 g, 10.1 ml,
1.0 eq.) and lithium hydroxide (0.05 g, 0.4 mmol, 0.1 eq.) were added
and the reaction mixture was allowed to warm to room temperature.
The reaction was stirred under argon for 3 h and quenched by the addi-
tion of brine (15 ml). The aqueous layer was extracted with diethyl ether
(3 × 15 ml). The combined organic extracts were washed with distilled
water, dried over Na2SO4, filtered through celite and concentrated
in vacuo. The crude products were purified using flash column chro-
matography (5% ethyl acetate in light petroleum affording 115 mg of
the side-product (4S)-3-acetyl-4-phenylmethyl-2-oxazolidinone. Further
purification of 190 mg of crude material by HPLC yielded 57 mg of the
major diastereomer (18);
1H NMR (400 MHz, CDCl3) δ = 7.29 (m, 5 H, Ph), 4.68 (m, 1 H, 4–H),
4.29 (m, 1 H, 3′–H), 4.15 (m, 3 H, 2 × 5–H, 5′–H), 3.30 (dd, 1 H, J = 3.4
and 13.5, 4–HA), 3.12 (m, 2 H, 2 × 2′–H), 2.79 (dd, 1 H, J = 9.5 and
13.5, 4–HB), 1.77 (m, 1 H, 4′–HA), 1.62 (m, 1 H, 4′–HB), 1.20 (d, 3 H,
J = 6.1, 6′–Me), 0.89 (9 H, s, t-Bu), 0.10 (6 H, s, Si(CH3)2); 13C NMR
(100 MHz, CDCl3) δ = 172.1, 153.4, 135.2, 129.5, 129.0, 127.4, 68.2,
66.9, 66.3, 55.1, 45.7, 43.0, 37.8, 25.9, 24.1, 18.0, –4.4, –4.0; υmax
(thin film)/cm–1 3500 (OH), 1784 (1–C = O), 1694 (1′–C = O) cm–1;
[α]D –12.5 (c 0.78 CHCl3); MS (ESI) m/z calc’d 444.2176684, found
444.2174280 [M + Na]+.
Synthesis of (4R,6R)-4-hydroxy-methyltetrahydropyran-2-one
(12) [43]. (4S)-3-[(3′R,5′R)-5′-[(t-Butyldimethylsilyl)oxy]-3′-hydroxyhexa-
noyl]-4-phenylmethyl-2-oxazolidinone (18) (0.02 g, 0.04 mmol, 1 eq.) was
dissolved in THF/H2O (4 ml, 3:1) and stirred under argon at 0°C and
hydrogen peroxide (20 µl, 0.19 mmol, 4.5 eq.) and lithium hydroxide
(2.3 mg, 0.01 mmol, 2.3 eq.) were added. The solution was warmed to
room temperature and stirred for 1.5 h. The reaction was quenched by
addition of sodium sulphite solution (170 µl, 0.26 mmol, 6 eq.), acidified
(pH 1) by the dropwise addition of 1 M HCl and stirred for 2 h at 40°C.
Following the addition of saturated brine (15 ml) the mixture was
extracted with DCM (10 × 50 ml), dried over Na2SO4 and concentrated
in vacuo. Flash column chromatography (light petroleum, light petro-
leum:ethyl acetate, 7:3) afforded the lactone 12 (1.0 mg, 18%) as a
colourless oil; 1H NMR (500 MHz, CDCl3) δ = 4.85 (ddq, 1 H, J = 3.0,
6.4 and 11.1, 6–H), 4.40 (m, 1 H, 4–H), 2.74 (dd, 1 H, J = 5.1 and 17.9,
3–Hax), 2.61 (ddd, 1 H, J = 1.7, 3.8 and 17.9, 3–Heq), 1.97 (dddd, 1 H,
J = 1.7, 3.0, 5.5 and 15.5, 5–Heq), 1.75 (ddd, 1 H, J = 3.4, 11.1 and
14.5, 5–Hax), 1.40 (t, 3 H, J = 6.4, C6–Me); 13C NMR (100 MHz, CDCl3)
δ = 170.2, 72.1, 62.9, 38.4, 37.7, 21.3; υmax (thin film)/cm–1 1725.0
(C = O) cm–1; [α]D +21 (c 0.05 CHCl3; Lit.[44] [α]D +23); MS (ESI) m/z
calc’d 153.0522134, found 153.0523200 [M + Na]+.
Supplementary material
Supplementary material including details about the construction of
expression plasmids pBgAR4 and pARE62 for the hybrid polyketide
synthases TKS–AR2 and TKS–AR4, respectively, is available at
http://current-biology.com/supmat/supmatin.htm.
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